Fimbrion Therapeutics Inc.
St. Louis, MO
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 20 S Sarah St, St. Louis, MO 63108, USA
- Website
- fimbrion.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Fimbrion Therapeutics Inc. is a for-profit corporate entity based in St. Louis, Missouri, registered in the System for Award Management (SAM.gov) with a current registration valid through August 2026. The company specializes in pharmaceutical research and development, focusing on creating novel small molecule compounds to address challenging infectious disease treatments. Their core scientific expertise appears centered on developing innovative antimicrobial drug candidates targeting complex bacterial infections with significant unmet medical needs.
Fimbrion Therapeutics Inc. has received multiple project grants from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program, each valued around $300,000. Their research focuses on developing targeted therapeutic interventions for challenging bacterial infections, including tuberculosis, non-tuberculous mycobacteria, Pseudomonas aeruginosa, and urinary tract infections. Specific research projects include developing thiazolino-pyridone compounds as novel antimycobacterial drugs, creating small molecule glycoside inhibitors to disrupt bacterial biofilm formation, designing heterocyclic inhibitors targeting specific respiratory proteins in mycobacteria, and developing antibody-recruiting molecules to prevent complicated urinary tract infections. Each grant represents a two-year research effort aimed at advancing preclinical development of potential new drug candidates with novel mechanisms of action to combat antimicrobial resistance and improve treatment outcomes for difficult-to-treat bacterial infections.
Quick answers
Is Fimbrion Therapeutics Inc. registered in SAM.gov?
Yes. Fimbrion Therapeutics Inc.'s SAM.gov registration is active through August 6, 2027.
What is Fimbrion Therapeutics Inc.'s CAGE code?
Fimbrion Therapeutics Inc.'s CAGE code is 5AAV6, and its Unique Entity ID (UEI) is N9RQX3G4EH54.
What is Fimbrion Therapeutics Inc.'s most recent federal award?
Fimbrion Therapeutics Inc.'s most recent federal grant award is Thiazolino-pyridone compounds as novel antimycobacterial drugs for tuberculosis (R43AI192175), from National Institute of Allergy and Infectious Diseases (NIH), on September 9, 2025.
On GovTribe
See Fimbrion Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors